International E-publication: Publish Projects, Dissertation, Theses, Books, Souvenir, Conference Proceeding with ISBN.  International E-Bulletin: Information/News regarding: Academics and Research

Illicit Drugs and their Assessment: A Brief Review

Author Affiliations

  • 1 Synthetic Organic and Medicinal Chemistry Laboratory, Mewar University, Chittorgarh Rajasthan, INDIA

Res. J. Forensic Sci., Volume 1, Issue (1), Pages 8-14, March,29 (2013)

Abstract

A lot of drug abuse treatment centers and health care providers have implemented special education programs for individuals who inject illicit drugs The recent reports conclude that drug abuse is on the rise. These drugs are moving into a mainstream category and are being used as frequently as drinking beer. The purpose of this article is to provide a brief outline on the assessment of these types of illicit drugs. Besides this it envisages specific drug classes like stimulants, sedatives, inhalants, Narcotic agents, Central Nervous System Stimulants etc., their unpleasant effects and structures.

References

  1. Wikler A. and Charles C.T., Opiate Addiction, Psychological and Neurophysiological Aspects in Relation to Clinical Problems. Springfield IL, (1953)
  2. Adler M.W., Drug and Alcohol Dependence, 37, 167-175 (1995)
  3. Dunn G.E., Rayan J.J., Dunn C.E., Trauma symptoms in substance abusers with and without histories of Childhood abuse, Journal of psychoactive Drugs, 26, 357-360 (1994)
  4. Gil-Rivas V., Fiorentine R., Anglin M.D., Sexual, Physical abuse and Posttraumatic stress disorder among women, Journal of psychoactive Drugs, 28, 95-102 (1996)
  5. Paoene D., Chavkin W., Willets I., Friedmann P. and Des Jarlais D., The impact of Sexual abuse: Implications for drug treatment, Journal of Women’s Health, 1, 149-153 (1992)
  6. Resnick H.S., Kilpatrick D.G., Dansky B.S., Sanders B.E. and Best CL., Prevalence of civilian trauma and Post-traumatic stress disorder in a representative sample of women, Journal of Consulting and Clinical Psychology, 61, 984-991 (1993)
  7. Teets J.M., Childhood sexual trauma of chemically dependent women, Journal of psychoactive Drug,27, 231-238 (1995)
  8. Windle M., Windle R., Scheidt D.M. and Miller G.B., Physical and sexual abuse and associated mental disorders among alcoholic inpatients, American Journal of Psychiatry, 152, 1322-1328 (1995)
  9. Finkelhor D., Hotaling G., Lewis I.A. and Smith C., Sexual abuse in a national survey of adult men and women: Prevalence, Characteristics and Risk factors: Child Abuse and Neglect, 14, 19-28 (1990)
  10. Kilpatrick D.G., Edmunds C.N. and Seymour A.K., Rape in America: A Report to the nation: Arlington, Virginia: National Victim Center and Charleston, South Carolina, Victims Research and Treatment Center, (1992)
  11. Tang Y.L., Wiste T.A., Mao P.X., Hou Y.Z., Journal of Substance Abuse Treatment,29, 215–220 (2005)
  12. Hibell B., Guttormsson U., Ahlstrom S., Balakireva O., Bjarnason T. and Kokkevi A., et al., The 2007 ESPAD Report: Substance use among students in 35 European countries, Stockholm: The Swedish Council for Information on Alcohol and Other Drugs (CAN), (2009)
  13. Julien R.M., Claire D. and Advokat J.E., A Primer of Drug Action. Edn 11, Worth Publishers, New York, 537 (2008)
  14. Baer D.M. and Elsie M.P., Environment and Behavior. Westview Press, 200 (1997)
  15. Hazardous Substances Data Bank, theobromine, casrn: 83-67-0
  16. Hardman J. and Limbird L., Goodman and Gilman's the pharmacological basis of therapeutics, McGraw-Hill, New York, 745 (2001)
  17. Howell L.L., Coffin V.L. and Spealman R.D., Behavorial and physiological effects of xanthines in nonhuman primates, Psychopharmacology, 129(1), 1-14 (1997)
  18. Gervase W. and Smith C., Cocoa and Chocolate, Routledge, London, 1765–1914 (2000)
  19. Maxwell K., A Sexual Odyssey: From Forbidden Fruit to Cybersex. Plenum, New York, 38–40 (1996)
  20. Methods and compositions for oral delivery of Areca and mate or theobromine, 04-28 (2005)
  21. Kelly C.J., Effects of theobromine should be considered in future studies, American Journal of Clinical Nutrition, 82, 486–8 (2005)
  22. Drevets W. et al., Amphetamine-Induced Dopamine Release in Human Ventral Striatum Correlates with Euphoria: Psychiatry, 49, 81–96 (2001)
  23. Schep L.J. and Slaughter R.J. and Beasley D.M., The clinical toxicology of metamfetamine: Clinical Toxicology (Philadelphia) 48(7), 675–94 (2010)
  24. Erowid Amphetamines Vault Effects, (1999)
  25. Amphetamines Better Health Channel, (2010)
  26. Vitiello B., Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function, Child Adolesc Psychiatr Clin N Am., 17(2), 459–74 (2008)
  27. Cruickshank C.C. and Dyer K.R., A review of the clinical pharmacology of methamphetamine, Addiction,104(7), 1085–99 (2009)
  28. Barr A.M., Panenka W.J., MacEwan G.W., Thornton A.E., Lang D.J., Honer W.G. and Lecomte T., The need for speed: an update on methamphetamine addiction, J. Psychiatry Neurosci., 31(5), 301–13 (2006)
  29. Darke S., Kaye S., McKetin R. and Duflou J., Major physical and psychological harms of methamphetamine use, Drug Alcohol Rev., 27(3), 253–62 (2008)
  30. Starling S.K. and Kumar A.J., Chem. Pharm. Res., 2(6), 244-252 (2010)